AMN Healthcare price target lowered to $34 from $47 at JMP Securities

JMP Securities analyst Constantine Davides lowered the firm’s price target on AMN Healthcare (AMN) to $34 from $47 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm reduced its 2025 EBITDA estimate to $235M from $250M on slightly more conservative operating margin assumptions and sees 2026 revenue of $2.66B on EBITDA of $255M, and its more conservative multiple is the result of continued near-term secular pressures within healthcare staffing, the analyst says.